- 5 clinical studies planned
- Objective to provide proof-of-concept by end of 2017
- 5 R&D projects activated
Noxopharm Limited (ASX:NOX) today posts its latest corporate presentation ahead of its AGM on 23 November 2016.
Dr Kelly, Noxopharm CEO, said, “The Company has embarked on an ambitious clinical trials program across a range of cancer types and in combination with chemotherapy or radiotherapy. The objectives are (a) to give ourselves the best chance to identify the best clinical indications to be pursued in registration studies, and (b) to provide evidence of proof-of-concept by the end of 2017.”
For further information please download PDF attached:
Download this document
